Echo | Angio | ECG | X-Ray/MRI | Clinical Trials | Guidelines | Drug Info |  Journals  | Events | Interesting Cases
Welcome May 30, 2012
Search News by Date
  
Daythree Daythree day4 Dayfive
Conference Highlights -  Nov 7, 2011 | Day One
Late Breaking News

DAY 1 HIGHLIGHTS

Optimal way to deliver TAVR is with a multidisciplinary team with the surgeon as the gatekeeper. Within this environment, the availability of TAVR improves the results of surgical aortic valve replacement.

Meta-analysis of EXAMINATION and DESERT trial: DES is associated with superior outcomes without greater risk in patients with STEMI

Discontinuing dual anti-platelet therapy early after stent implantation increases the risk of stent thrombosis

New stem cell therapies show promising results in treatment of severe heart disease

Stent Grafts are effective in SFA patients with moderate and long lesions

CLOSURE I: PFO Device+Medical Therapy is non-superior to medical therapy alone

GHOST: Accurate medical history can predict adherence to dual antiplatelet therapy
On further stastistical analysis to assess agreement between physicians, in which a score higher than 0.81 indicated almost perfect agreement, the data yielded a score of 0.889.


ACTIVE: Cobalt Chromium Stents show favorable results in the treatment of PVD
The stent demonstrated a remarkable safety profile associated with high technical, procedural and clinical success and efficacy


Precise assessment of "Risk creep" to avoid an inappropriate increased number of low-risk or reduced high-risk patients for receiving TAVR
The Logistic EuroSCORE grossly overestimates risk in high-risk populations but cannot be dismissed completely as it categorizes risk.


Survival with DES is noninferior to BMS in patients with STEMI
In terms of stent-oriented endpoints, the Xience V stent significantly reduced the target vessel revascularization and target lesion revascularization and the rates of stent thrombosis


Safety and feasibility of stem cells in patients with chronic ischemic cardiomyopathy
New stem cell therapies show promising results in severe heart disease


Efficacy of nitinol stent in patients with occlusive SFA disease and moderate long lesions
Stent Grafts are effective in SFA patients with moderate, long lesions


Advantages of Prasugrel and Ticagrelor over Clopidogrel in protecting high-risk patients
More rapid, intensive and predictable platelet inhibition is provided by both prasugrel and ticagrelor and these two drugs significantly reduce stent thrombosis regardless of stent type.


CLOSURE I study closes with failure: inability to identify the "optimal" patient population due to insufficient specificity
Alternative explanations unrelated to paradoxical embolism presented in 80% of patients with a current stroke and a higher incidence of atrial fibrillation was associated with closure of the device.

Today's Spotlight


Early Discontinuation of DAPT increases the risk of stent thrombosis following stent implantation
DAPT discontinuation before 30 days increased the risk of stent thrombosis among those who received everolimus-eluting stents, but discontinuation after 30 days, however, did not appear to increase the risk.

Disclaimer

Independent authors develop the materials available on this site, and do not reflect a publication of TCT 11. These are not sanctioned or commercially supported by TCT 11. They do not constitute an official part of that conference. Healthcare professionals should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before using them for any purposes. Site will not be held responsible for any discrepancies or disputes arising due to use of such data.
<< Back
About Us | Disclaimer |  Privacy Statement | Advertising Info 
info@centrixhealthcare.com © Copyright 2000-2012 Centrix Healthcare Inc. - All Rights Reserved.